Figure 5: Overall survival (OS) and progression-free survival (PFS) based on the absolute lymphocyte count/absolute monocyte count ratio at day 15 (ALC/AMC-15) for patients with an ALC-15 < 500 cells/Ál and an AMC < 600 cells/Ál (group 2) and patients with an ALC-15 = 500 cells/Ál and an AMC = 600 cells/Ál (group 3) postautologous peripheral hematopoietic stem cell transplantation (APHSCT). OS (5a and 5c) and PFS (5b and 5d) times were superior in groups 2 and 3 patients with an ALC/AMC-15 = 1.